SCHEMBL5543973

SCHEMBL5543973

O=COCCc1nnnn1-c1cccc(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.45
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 4/20 0.42
MAPT P10636 1/20 0.40
HSD11B1 P28845 4/20 0.40
PKM P14618 1/20 0.38
NLRP3 Q96P20 1/20 0.38
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.37
CNKSR1 Q969H4 1/20 0.37
NOTUM Q6P988 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
TSHR P16473 1/20 0.36
BRCA1 P38398 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536571 0.86 HSD11B1 (0.44) POLBLMNAHTTALDH1A1MAPT
SCHEMBL5537091 0.86 ALDH1A1 (0.42) LMNAHTTALDH1A1MAPTHSD11B1
SCHEMBL5543439 0.85 ALDH1A1 (0.48) LMNAHTTL3MBTL1ALDH1A1MAPT
SCHEMBL5548019 0.85 HSD11B1 (0.53) POLBLMNAHTTL3MBTL1ALDH1A1
SCHEMBL5543968 0.82 POLB (0.48) POLBLMNAHTTL3MBTL1ALDH1A1
SCHEMBL5543817 0.79 ALDH1A1 (0.31) L3MBTL1ALDH1A1
SCHEMBL5546087 0.77 HSD11B1 (0.50) POLBLMNAHTTL3MBTL1ALDH1A1
SCHEMBL5537177 0.77 ALDH1A1 (0.49) LMNAHTTL3MBTL1ALDH1A1HSD11B1
SCHEMBL25250741 0.76 LMNA (0.54) POLBLMNAHTTL3MBTL1ALDH1A1
SCHEMBL5543115 0.76 POLB (0.52) POLBLMNAHTTL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 POLB 1637/4885LMNA 4152/4885HTT 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.